id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-E-5262-0007,FDA,FDA-2019-E-5262,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2024-12-18T05:00:00Z,2024,12,2024-12-18T05:00:00Z,,2024-12-18T19:19:25Z,,0,0,090000648687bf70
FDA-2019-E-5262-0006,FDA,FDA-2019-E-5262,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2024-01-19T05:00:00Z,2024,1,2024-01-19T05:00:00Z,,2024-01-19T13:05:39Z,,0,0,09000064863a8c37
FDA-2019-E-5262-0005,FDA,FDA-2019-E-5262,Letter from U. S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-01-17T05:00:00Z,2024,1,2024-01-17T05:00:00Z,,2024-01-17T19:19:56Z,,0,0,0900006486390228
FDA-2019-E-5262-0004,FDA,FDA-2019-E-5262,Determination of Regulatory Review Period for Purposes of Patent Extension; Nuzyra Injection (New Drug Application 209817),Notice,Determinations,2023-11-30T05:00:00Z,2023,11,2023-11-30T05:00:00Z,2024-05-29T03:59:59Z,2023-11-30T18:17:29Z,2023-26363,0,0,09000064862c3351
FDA-2019-E-5262-0003,FDA,FDA-2019-E-5262,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2019-12-23T05:00:00Z,2019,12,2019-12-23T05:00:00Z,,2019-12-23T19:25:55Z,,0,0,090000648424b3fb
FDA-2019-E-5262-0001,FDA,FDA-2019-E-5262,Letter from U S Patent and Trademark Office,Other,Letter(s),2019-11-07T05:00:00Z,2019,11,2019-11-07T05:00:00Z,,2019-11-07T16:11:00Z,,0,0,09000064841291b9
FDA-2019-E-5262-0002,FDA,FDA-2019-E-5262,"Patent Term Extension Application from Paratek Pharmaceuticals, Inc",Other,Application,2019-11-07T05:00:00Z,2019,11,2019-11-07T05:00:00Z,,2019-11-07T16:12:32Z,,0,0,09000064841291ba